Major Depressive Disorder - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Major Depressive Disorder - Pipeline Review, H2 2013 market report to its offering
Major Depressive Disorder - Pipeline Review, H2 2013


, 'Major Depressive Disorder - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Major Depressive Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Major Depressive Disorder. Major Depressive Disorder - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Major Depressive Disorder.
- A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Major Depressive Disorder pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Bristol-Myers Squibb Company
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
AstraZeneca PLC
Eli Lilly and Company
Alkermes, Inc.
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Taisho Pharmaceutical Co., Ltd.
Neurocrine Biosciences, Inc.
Gedeon Richter Plc.
H Lundbeck A/S
Laboratoires Pierre Fabre SA
Les Laboratoires Servier
Shire Plc
OPKO Health, Inc.
Neuralstem, Inc.
Suven Life Sciences Ltd.
e-Therapeutics plc
Intas Pharmaceuticals Ltd.
Angelini Group
Fabre-Kramer Pharmaceuticals, Inc.
CeNeRx BioPharma, Inc.
Dart NeuroScience LLC
M's Science Corporation
BrainCells Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sinil Pharma Ltd.
Reviva Pharmaceuticals Inc.
Naurex, Inc.
PharmaNeuroBoost N.V.

To view the table of contents for this market research report please visit